Untreated (n = 40) | Virally suppressed (n = 115) | P value | |
---|---|---|---|
Demographic data | |||
Median age in years (IQR) | 36 (32–44) | 47 (43–54) | < 0.0001a |
Gender -female n (%) | 28 (70) | 96 (83.5) | 0.0019b |
Clinical data | |||
Median Years on treatment (IQR) | N/A | 9 (7–12) | |
Missing data | n = 26 | ||
Median current CD4 count cells/cm3 (IQR). | N/A | 503 (329–633) | |
Missing data | n = 7 | ||
Median baseline CD4 count cells/cm3 (IQR) | 299 (160–486) | 147 (65–217) | < 0.0001a |
Missing data | n = 5 | n = 41 | |
Current ART regimen (%) | |||
NNRTI based first line regimen | N/A | 94(81.7) | |
PI based second line regimen | N/A | 20 (17.4) | |
Missing data | 1 (0.9) | ||
HIV quantification | |||
Median Viral load copies/ml (IQR) | 45,837 (7325-176350) | N/A | |
Median proviral load copies/million PBMCs(IQR) | 1422 (571–2831) | 464.3 (235–758) | < 0.0001a |
Serology-positive (%) | |||
Hepatitis C | 2 (1.73) | ||
Epstein Barr virus | 115 (100) | ||
Cytomegalovirus | 107 (93.0) |